Phase I/II study of VEGFR1/2-derived peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for metastatic colorectal cancer with KRAS genetic mutation as a third-line therapy

ABSTRACT: Interventions: KRAS genetic sequence, peptide vaccination, TS1 Primary outcome(s): First step (clinical phase I) Primary Endpoint: RD Second step (clinical phase II) Primary Endpoint: DCR Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2618327 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR